がん細胞ウイルス療法市場：ウイルスタイプ、用途、最終用途別-2025-2030年の世界予測

がん細胞ウイルス療法市場は、2023年に1億1,753万米ドルと評価され、2024年には1億3,250万米ドルに達すると予測され、CAGR 15.45%で成長し、2030年には3億2,130万米ドルに達すると予測されています。

がん細胞ウイルス療法は、がん治療における有望なフロンティアであり、正常組織を温存しながらがん細胞に選択的に感染して破壊する、遺伝子操作されたウイルスまたは天然に存在するウイルスの使用に焦点を当てています。がんの有病率の上昇と従来の治療法の限界は、このような革新的なアプローチの必要性を強調しています。これらの治療法は、メラノーマ、神経膠芽腫、膵臓がんなど、さまざまながんの治療に応用されており、主にヘルスケア機関や研究所で使用されています。この市場は、遺伝子工学の進歩、がん研究への投資の増加、標的治療への需要の高まりなど、いくつかの主要成長要因の影響を受けています。この市場の大きなビジネスチャンスは、免疫療法や化学療法とオンコリティック・ウイルスの相乗効果を活用することで、有効性を高め、治療範囲を拡大する併用療法の開拓にあります。

成長に影響を与える主な制限には、厳しい臨床試験要件や潜在的な安全性懸念による規制上のハードル、腫瘍へのウイルスの送達と標的化に関する課題などがあります。さらに、高い研究開発コストと強力なプレーヤーによる競合情勢が大きな課題となっています。とはいえ、ウイルスの選択性や効力の強化、新たな送達方法の開発、新規ウイルス株の探索といった技術革新の領域は、事業成長の大きな機会をもたらしています。市場の性質については、現在、官民双方から多額の投資が行われており、黎明期ではあるが急速に進化している段階にあります。利害関係者への調査提言としては、学術機関やバイオテクノロジー機関との提携を促進して研究を推進し競争優位性を維持すること、世界に提携を拡大して市場浸透を強化すること、特定の患者サブセットに対応する個別化医療アプローチに注力して臨床と市場での成功を最大化することなどが挙げられます。

市場力学：急速に進化するがん細胞ウイルス療法市場の主要市場インサイトを公開

がん細胞ウイルス療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界人口におけるがん罹患率の上昇
  • 免疫療法普及のための啓発プログラム
• 市場抑制要因
  • がん細胞ウイルス療法に関連するリスクと合併症
• 市場機会
  • 先進的ながん細胞ウイルス療法を開発するための継続的な研究開発
  • 精密医療戦略としてのがん細胞ウイルス療法の台頭
• 市場の課題
  • オンコライトウイルス療法を取り巻く複雑な規制の枠組み

ポーターのファイブフォース：がん細胞ウイルス療法市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん細胞ウイルス療法市場における外部からの影響の把握

外部マクロ環境要因は、がん細胞ウイルス療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん細胞ウイルス療法市場における競合情勢の把握

がん細胞ウイルス療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん細胞ウイルス療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん細胞ウイルス療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん細胞ウイルス療法市場における成功への道筋を描く

がん細胞ウイルス療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界人口におけるがん発症率の上昇
    • 免疫療法を促進するための啓発プログラム
  • 抑制要因
    • がん細胞ウイルス療法に関連するリスクと合併症
  • 機会
    • 先進的ながん細胞ウイルス療法を開発するための継続的な研究開発
    • 精密医療戦略としてのがん細胞ウイルス療法の台頭
  • 課題
    • 腫瘍溶解性ウイルス療法を取り巻く複雑な規制枠組み
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん細胞ウイルス療法市場ウイルスの種類別

• 遺伝子組み換え腫瘍溶解性ウイルス
• 腫瘍溶解性野生型ウイルス

第7章 がん細胞ウイルス療法市場：用途別

• 乳がん
• 肺がん
• 悪性黒色腫
• 卵巣がん
• 前立腺がん

第8章 がん細胞ウイルス療法市場：最終用途別

• がん調査機関
• 病院
• 専門クリニック

第9章 南北アメリカのがん細胞ウイルス療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のがん細胞ウイルス療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのがん細胞ウイルス療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amunbio Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• BioInvent International AB
• Boehringer Ingelheim International GmbH
• Calidi Biotherapeutics, Inc.
• Candel Therapeutics
• Daiichi Sankyo Company Ltd.
• Elicera Therapeutics AB
• EpicentRx, Inc.
• Genelux Corporation
• Hookipa Pharma Inc.
• Imvaq Therapeutics
• Istari Oncology, Inc.
• Johnson & Johnson Services, Inc.
• Lokon Pharma AB
• Merck & Co., Inc.
• Orgenesis Inc.
• Pfizer, Inc.
• Protheragen Inc.
• Seneca Therapeutics, Inc.
• Takara Bio Inc.
• TILT Biotherapeutics
• Treovir LLC
• Wuhan Binhui Biotechnology Co Ltd

LIST OF FIGURES

• FIGURE 1. ONCOLYTIC VIRUS THERAPIES MARKET RESEARCH PROCESS
• FIGURE 2. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ONCOLYTIC VIRUS THERAPIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ONCOLYTIC VIRUS THERAPIES MARKET DYNAMICS
• TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY ENGINEERED ONCOLYTIC VIRUSES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ONCOLYTIC WILD-TYPE VIRUSES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 147. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

The Oncolytic Virus Therapies Market was valued at USD 117.53 million in 2023, expected to reach USD 132.50 million in 2024, and is projected to grow at a CAGR of 15.45%, to USD 321.30 million by 2030.

Oncolytic virus therapies represent a promising frontier in cancer treatment, focusing on the use of genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells while sparing normal tissues. The rising prevalence of cancer, coupled with the limitations of traditional therapies, underscores the necessity for such innovative approaches. These therapies are applied in the treatment of a variety of cancers, including melanoma, glioblastoma, and pancreatic cancer, among others, and are primarily used by healthcare institutions and research laboratories. The market is influenced by several key growth factors, including advances in genetic engineering, increasing investment in cancer research, and the growing demand for targeted therapies. A major opportunity within this market lies in the development of combination therapies, which leverage the synergistic effects of oncolytic viruses with immunotherapies or chemotherapies, thereby enhancing efficacy and broadening therapeutic scope.

The major limitations impacting growth include regulatory hurdles due to stringent clinical trial requirements and potential safety concerns, as well as challenges related to the delivery and targeting of viruses to tumors. Additionally, high R&D costs and a competitive landscape with strong players pose significant challenges. Nonetheless, areas of innovation like the enhancement of virus selectivity and potency, the development of new delivery methods, and exploration of novel virus strains present vast opportunities for business growth. As for market nature, it is currently in a nascent but rapidly evolving stage with significant investments from both public and private sectors. Recommendations for stakeholders include fostering collaborations with academic and biotech institutions to drive research and maintain competitive advantage, expanding partnerships globally to enhance market penetration, and focusing on personalized medicine approaches to cater to specific patient subsets, thus maximizing clinical and market success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncolytic Virus Therapies Market

The Oncolytic Virus Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of cancer among the global population
  • Awareness program to promote immunotherapy
• Market Restraints
  • Risk and complication associated with oncolytic virus therapies
• Market Opportunities
  • Ongoing R&D to develop advanced oncolytic virus therapies
  • Rise of oncolytic virus therapies as a precision medicine strategy
• Market Challenges
  • Complex regulatory framework surrounding oncolytic virus therapy

Porter's Five Forces: A Strategic Tool for Navigating the Oncolytic Virus Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncolytic Virus Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncolytic Virus Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncolytic Virus Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncolytic Virus Therapies Market

A detailed market share analysis in the Oncolytic Virus Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncolytic Virus Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncolytic Virus Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncolytic Virus Therapies Market

A strategic analysis of the Oncolytic Virus Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncolytic Virus Therapies Market, highlighting leading vendors and their innovative profiles. These include Amunbio Inc., Astellas Pharma Inc., AstraZeneca PLC, BioInvent International AB, Boehringer Ingelheim International GmbH, Calidi Biotherapeutics, Inc., Candel Therapeutics, Daiichi Sankyo Company Ltd., Elicera Therapeutics AB, EpicentRx, Inc., Genelux Corporation, Hookipa Pharma Inc., Imvaq Therapeutics, Istari Oncology, Inc., Johnson & Johnson Services, Inc., Lokon Pharma AB, Merck & Co., Inc., Orgenesis Inc., Pfizer, Inc., Protheragen Inc., Seneca Therapeutics, Inc., Takara Bio Inc., TILT Biotherapeutics, Treovir LLC, and Wuhan Binhui Biotechnology Co Ltd.

Market Segmentation & Coverage

This research report categorizes the Oncolytic Virus Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Virus Type, market is studied across Genetically Engineered Oncolytic Viruses and Oncolytic Wild-type Viruses.
• Based on Application, market is studied across Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, and Prostate Cancer.
• Based on End Use, market is studied across Cancer Research Institutes, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of cancer among the global population
    • 5.1.1.2. Awareness program to promote immunotherapy
  • 5.1.2. Restraints
    • 5.1.2.1. Risk and complication associated with oncolytic virus therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D to develop advanced oncolytic virus therapies
    • 5.1.3.2. Rise of oncolytic virus therapies as a precision medicine strategy
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory framework surrounding oncolytic virus therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncolytic Virus Therapies Market, by Virus Type

• 6.1. Introduction
• 6.2. Genetically Engineered Oncolytic Viruses
• 6.3. Oncolytic Wild-type Viruses

7. Oncolytic Virus Therapies Market, by Application

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Lung Cancer
• 7.4. Melanoma
• 7.5. Ovarian Cancer
• 7.6. Prostate Cancer

8. Oncolytic Virus Therapies Market, by End Use

• 8.1. Introduction
• 8.2. Cancer Research Institutes
• 8.3. Hospitals
• 8.4. Specialty Clinics

9. Americas Oncolytic Virus Therapies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Oncolytic Virus Therapies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Oncolytic Virus Therapies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amunbio Inc.
• 2. Astellas Pharma Inc.
• 3. AstraZeneca PLC
• 4. BioInvent International AB
• 5. Boehringer Ingelheim International GmbH
• 6. Calidi Biotherapeutics, Inc.
• 7. Candel Therapeutics
• 8. Daiichi Sankyo Company Ltd.
• 9. Elicera Therapeutics AB
• 10. EpicentRx, Inc.
• 11. Genelux Corporation
• 12. Hookipa Pharma Inc.
• 13. Imvaq Therapeutics
• 14. Istari Oncology, Inc.
• 15. Johnson & Johnson Services, Inc.
• 16. Lokon Pharma AB
• 17. Merck & Co., Inc.
• 18. Orgenesis Inc.
• 19. Pfizer, Inc.
• 20. Protheragen Inc.
• 21. Seneca Therapeutics, Inc.
• 22. Takara Bio Inc.
• 23. TILT Biotherapeutics
• 24. Treovir LLC
• 25. Wuhan Binhui Biotechnology Co Ltd